Bahar Dasgeb, MD
Dermatology · New Brunswick, NJNPI 1760506059
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,506 of the $13,808 with a category attached, or 90.6%. Regeneron accounts for 63.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $8,703 and has fallen 99.8% since, to $16 in 2024.
Across 18 payments — averaging $767.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$9K
- Regeneron Healthcare Solutions, Inc.$3K
- Sanofi$2K
- Sun Pharmaceutical Industries Inc.$16
Across 12 payments — averaging $3183.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$25K
- Daiichi Sankyo Inc.$13K
What the payments were for
- Consulting fees$12,50691%
- Travel & lodging$8186%
- Food & beverage$4844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 14 | $8,753 |
| Regeneron Healthcare Solutions, Inc. | 2 | $3,223 |
| Sanofi | 1 | $1,816 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$13,282
How this compares
$13,808 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErivedgeVismodegib | 22 | $286,871 |
| Clobetasol Propionate | 51 | $3,715 |
| Clindamycin Phosphate | 14 | $2,472 |
| Tacrolimus | 17 | $2,056 |
| Triamcinolone Acetonide | 74 | $1,373 |
| Imiquimod | 46 | $1,097 |
| ValacyclovirValacyclovir Hcl | 20 | $714 |
| Doxycycline Hyclate | 19 | $387 |
| Nystatin | 16 | $226 |
| Fluconazole | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Brunswick
- Daniel GrabellNew Brunswick$113K
- Omar NoorSomerset$4.5M
- Linda Cappiello-LindsleyHoboken$2.3M
- Brian KeeganEast Windsor$1.7M
- Jerry BagelEast Windsor$1.6M
- Mital Patel CohenFlorham Park$799K
- Ronald BernardinVoorhees$688K
- Brian MachlerFlorham Park$346K
- Jeanine DownieMontclair$327K
- Aanand GeriaRutherford$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.